It is pivotal to identify protein-protein interaction in situ to understand protein function. Conventional methods to determine the interaction of proteins destruct tissue or are applicable to cell culture only. To identify association of proteins in cells in tissue, we adapted indirect double-labeling immunofluorescence and combined it with conventional confocal laser scanning microscopy (CLSM) to measure fluorescence resonance energy transfer (FRET). As a model system, we chose caveolin-1a and caveolin-2, two major components of endothelial caveolae, and examined their interaction in the endothelium of vessels in fixed tissues of laboratory animals and human glomus tumors. Several methodological aspects were examined. Measuring the absolute increase in fluorescence (DIF) was superior compared to determining the relative FRET efficiency, because it is more robust against small increases of fluorescence during measurements that results from unavoidable minimal crossreactivity of the secondary antibodies. Both, sequential and simultaneous incubation of secondary antibodies result in robust and reliable increases in DIF. If incubated sequentially, however, the acceptor-labeled secondary antibody should be applied first. The size of the secondary reagent (F(ab 0 ) 2 vs whole antibody) has no major influence. In conclusion, CLSM-FRET can measure close spatial association of proteins in situ and can be applied to human surgical material.
To understand the function of a protein, it is pivotal to identify interacting proteins that modulate its function and to determine where and under what circumstances they interact within a cell. Many techniques have been developed to identify proteinprotein association in cell culture and in tissue homogenates. Such approaches, however, provide only very limited information about the situation in situ. Cell culture gives detailed information only for a system reduced greatly in complexity, and tissue homogenates give no information in which cell type the interaction occurs. Therefore, it is desirable to detect a close spatial association of proteins in a given cell within a tissue, including identification of the cellular compartment in which it occurs. A simple method to study the localization of two proteins in tissue is double-labeling immunohistochemistry on tissue sections. At the conventional light microscopic level, the maximum spatial resolution is about 200 nm 1 which is not sufficient to determine if proteins are located close enough to allow interaction. Fluorescence resonance energy transfer (FRET) is a nonradiative transfer of energy between two fluorophores, an energy-donating fluorophore called the donor, and an energy-accepting fluorophore called the acceptor. 2, 3 Since the efficiency of energy transfer is reduced by the sixth order of magnitude of the distance between these fluorophores, 2 efficient energy transfer between two fluorophores occurs for most fluorophore pairs only if they are o10 nm apart. This effect can be exploited to detect close spatial association of proteins by labeling them with fluorophores. Direct labeling of two proteins, either directly or by genetic means, alters the protein itself and/or its endogenous level in the cell. This may not reflect the situation found in situ. Furthermore, these techniques are not applicable to human material and, hence, do not allow analysis of pathological specimens. An easy and affordable method to label endogenous proteins with fluorescent dyes in tissue sections that can be applied to human material is immunofluorescence. Indeed, direct and indirect immunofluorescence have been successfully used to detect protein-protein interactions in cell culture. 3 Direct labeling of small amounts of antibodies with fluorophores can, in principle, be done with commercially available kits but most commercially available antibodies are mixed with substantial amounts of other proteins that interfere with the labeling reaction which limits its practical application.
So far two studies have employed indirect immunofluorescence for FRET experiments in tissue sections. One detected spatial association of proteins in pathologic protein aggregates not reflecting a physiologic concentration of proteins 4 and the other used a sophisticated and not generally available two photon setup. 5 The goal of our study was to develop a method to use indirect immunofluorescence to detect a close spatial association of two proteins whose expression is not pathologically altered in tissue sections using a conventional confocal laser scanning microscopy (CLSM). As a model system we chose to examine the interaction of caveolin-1a (cav-1a) and caveolin-2 (cav-2), two major proteins of caveolae that are known to form hetero-oligomers. 6 Since the transport of cav-2 to caveolae is dependent on the coexpression of cav-1, 7, 8 it is safe to assume that both proteins interact also in caveolae and are a valid model to test the applicability of doublelabeling immunohistochemistry and FRET. Indeed, we were able to detect a FRET signal in endothelial cells using indirect immunofluorescence in tissue sections of specimens obtained from a laboratory animal (rat) under controlled conditions. We could further prove that the technique is also applicable to tissue sections from human tissue that was retrieved through surgical procedures.
Materials and methods

Chemicals
All chemicals were obtained from Sigma, Deisenhofen, Germany, unless otherwise stated.
Tissue Preparation
Wistar rats of either sex (n ¼ 16) were killed by inhalation of isoflurane (Abbott, Wiesbaden, Germany). The thorax was opened and the lungs were inflated via the trachea using a 50% OCT compound (Sakura, Zoeterwoude, The Netherlands) in phosphate-buffered saline (PBS). Then, the thoracic organs were jointly removed, oriented in OCT compound on a piece of filter paper, and snap frozen in melting isopentane.
Double-Labeling Immunohistochemistry
Different incubation protocols were used and evaluated for their suitability for further FRET analysis. The following protocol was used and subsequently modified:
Ten micrometer thick sections were cut using a Leica CM-1900 cryostat (Leica, Bensheim, Germany), mounted on slides and subsequently dipped for 10 min in ice-cold acetone. Then, sections were incubated for 1 h at room temperature with 5% normal goat serum and 5% bovine serum albumin in PBS.
Then, sections were incubated overnight with rabbit cav-1a antibody (1:400; Santa Cruz Biotechnology, Hamburg, Germany) together with a monoclonal mouse cav-2 antibody (1:200, Transduction Laboratories, Lexington, KY, USA) as mixture in PBS with normal salt concentration (0.9% NaCl, PBS) or doubled salt concentration (1.8% NaCl). After washing with PBS, the sections were incubated for 1 h with donkey anti-mouse IgG Cy3-conjugated antibody (1:1 000) and donkey antirabbit IgG Cy5-conjugated antibody (1:50) that both were crossadsorbed against rat serum proteins as well as serum proteins from the species of the other primary antibody (both from Dianova, Hamburg, Germany). After the final washing step, sections were fixed for 10 min in 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4, and washed three times in PBS. This fixation step proved to extend the stability of the labeling. Subsequently, the sections were coverslipped with carbonate-buffered glycerol, pH 8.6, or Mowiol 4-88, pH 8.6 , and stored at 41C until evaluation. No differences were noted between the two mounting media with regard to bleaching of Cy5 and FRET signal. Coverslips of moviol-embedded sections, however, are less prone to dislocation since moviol hardens.
Slides that were incubated with a specific combination of antibodies were washed in separate cuvettes to prevent diffusion and subsequent binding of small amounts of primary antibody from other sections. This procedure was applied to all incubations.
The following modifications of the protocol were applied (sections from n ¼ 4 animals each):
1. To verify that the measured FRET signal was not originating from crossreactivity of secondary antibodies, the cav-2 or the cav-1a antibody, respectively, was omitted. 2. To evaluate if minimal amounts of bound donorlabeled antibodies still give a FRET signal the following incubation scheme was applied: The cav-1a antibody was labeled using donkey antirabbit IgG Cy5-conjugated antibody (1:50) simultaneously with donkey anti-rabbit IgG Cy3-conjugated antibody that was serially diluted from 1:2000 to 1:32 000. 3. To assess if the sequence of the application of the secondary antibodies influences the intensity of the FRET signal, the order of incubation of the secondary reagents was reversed. 4. To assess if the size of the secondary reagent influences the amount of the FRET signal, the Cy5-conjugated anti-rabbit IgG antibody was replaced with a donkey anti-rabbit IgG Cy5-conjugated F(ab 0 ) 2 fragment (Dianova). 5. To assess if sequential application of antibodies is superior to simultaneous application, secondary antibodies were either applied simultaneously or sequentially with a washing step in between.
As further control, we performed a FRET experiment with cav-2 and the a10 nicotinic acetylcholine receptor subunit that is expressed in heart 9 and has been described in a subset of endothelial cells 10 but, as all other nicotinic receptor subunits, has not been described as an interacting partner of cav-2. To detect the a10 nicotinic acetylcholine receptor subunit, we used a rabbit polyclonal antibody directed against the amino acids 404-417 of the protein. 11 For the detection, the same secondary reagents were used as in the cav-1-2 experiments.
To assess if we still detect an interaction between both cav isoforms if donor and acceptor label are switched, we labeled the cav-2 antibody with a donkey anti-mouse IgG Cy5-conjugated antibody (Dianova) and the cav-1 antibody with a donkey anti-rabbit IgG Cy3-conjugated antibody (Chemicon, Hampshire, UK).
Application to Human Pathological Material
To assess if the method is applicable to human tissue that was removed during surgical procedures, sections from glomus tumors that were Zamboni fixed (1.85% formaldehyde and 15% saturated picric acid solution in 0.1 M phosphate buffer, pH 7.4) and cryoprotected (18% sucrose in 0.1 M phosphate buffer, pH 7.4) were incubated as described above using the optimized protocol. The glomus tumors were obtained during the years 1997-2003 (n ¼ 4), anonymized, and stored at À801C until use.
Measurement of FRET
FRET was measured with the acceptor bleaching method using a Leica CLSM TCS SP2 AOBS equipped with an oil immersion objective Â 63, 1.4. NA (Leica, Bensheim, Germany). The following settings were used throughout the experiments: excitation for Cy3: HeNe laser with 543 nm (51% intensity), excitation for Cy5: HeNe laser 633 nm (20% laser intensity); detection wavelength for Cy3: 550-602 nm, detection wavelength for Cy5: 642-705 nm. The pinhole was set to 3 airy units. Photomultiplier tube (PMT) settings were between 480 and 591 V to measure in the linear range of the PMT. Gain and laser intensity for detection were held constant during an experiment. The two fluorophores were detected sequentially in a line-by-line mode. Thus, only the adequate laser for each fluorophore was switched on to prevent the excitation of the other fluorophore and no crosstalk between both channels was detected even at higher PMT settings than the ones used for FRET experiments.
FRET was assessed in endothelial cells in tissue sections of the rat mediastinum including the heart.
The measurements were performed with the FRET acceptor bleaching application of the CLSM software as follows: Before and after bleaching, images in the Cy3(donor)-and the Cy5(acceptor) channel were acquired in the line-by-line sequential mode with three averaging steps to reduce noise. Cy5 was bleached 5-10 times (1.28 s/scan) with highest possible zoom ( Â 32) with 100% laser power of the 633 nm HeNe laser line. The number of bleaching steps that were sufficient to bleach Cy5 was determined at the beginning of each experiment and was held constant throughout. FRET was quantified by measurement of the fluorescence intensity in the Cy3(donor) channel in the bleached area before and after bleaching. Since the squaresized bleaching area also included the vascular lumen or other nonlabeled parts of the tissue, a second measurement was performed outlining the endothelial cell using the freehand region of interest (ROI) encircling tool of the software.
To assess changes during the measurements that were not due to FRET, four rectangular sentinel ROIs of approximately the same size as the bleached area were measured adjacent to the bleached area. Measurements were discarded if changes in FRET signal in these ROIs were obvious. Six measurements were performed for each animal and experimental condition.
Statistical Analysis
The resulting change in fluorescence intensity was depicted as (a) FRET efficiency (FRET eff ) expressed as percentage of fluorescence increase calculated by: FRET eff ¼ ((I DA ÀI DB )/I DA ) Â 100, and (b) change of fluorescence intensity (absolute increase in fluorescence (DIF)) ¼ I DA ÀI DB , where I DA is the donor intensity after bleaching and I DB the donor intensity before bleaching.
To compare two experimental conditions and their controls, all groups of the experiment were compared by Kruskal-Wallis test. If the resulting P-value was o0.05, two individual groups were compared by Mann-Whitney tests in a hierarchical order.
12 Specifically, we firstly tested experimental conditions vs respective control conditions, then two experimental conditions against each other. The comparison was rated significant if Po0.05 and hierarchical testing of individual groups was stopped if P40.05 to correct for multiple testing. To assess if DIF or FRET eff is superior to discriminate between FRET experiments and controls, their receiving operator characteristics (ROC) curves were generated and the areas under each curve were compared using the method of Hanley. 13 To test whether the size of the secondary antibody and the mixing or sequential application of both secondary antibodies determines the intensity of the FRET-signal, we varied the size of the secondary reagent using a Cy5-labeled F(ab 0 ) 2 fragment instead of a Cy5-labeled whole IgG molecule as well as sequential application of both secondary antibodies vs mixing antibodies. To allow for a possible interaction between these factors, we performed an analysis of variance analyzing DIF depending on the factors (a) size of antibody, (b) mode of application and (c) their interaction.
All statistical analysis was performed using SPSS versions 11.5.1 or 12.0 (SPSS GmbH Software, Munich, Germany) except for ROC curve analysis which was performed using MedCalc version 8.1.0.0 (MedCalc Software, Mariakerke, Belgium).
Results
Detection of FRET between cav-1a and cav-2 in Tissue Sections and Negative Controls
Using standard indirect immunofluorescence technique, FRET was robustly detected in endothelial cells in tissue sections of the rat mediastinum by bleaching the acceptor (Cy5) and detecting the increase in donor (Cy3) fluorescence. A doublelabeling of cav-1 and cav-2 is shown in Figure 1 and a FRET experiment is shown in Figure 2 . To test for crossreactivity of secondary antibodies, one of the primary antibodies was omitted but both secondary antibodies were applied ( Figure 3 ). If that primary antibody was omitted which was normally detected with a Cy5-labeled secondary antibody, no FRET signal was obtained (median: FRET eff 0%, DIF À0.56) and there was no statistically significant difference compared to a single incubation with one primary antibody labeled with Cy3-conjugated secondary antibody (median: FRET eff 0%, DIF À1.00). Since we measured a negative DIF in this experiment, a small decrease in Cy3 fluorescence either due to the bleaching procedure or occurring during the image acquisition was present, indicating that the FRET signal is underestimated. In contrast, omission of that primary antibody which was normally labeled with Cy3-conjugated secondary antibody, resulted in detectable FRET signal when both secondary antibodies were applied (median: FRET eff 10.94%, DIF 2.99) although DIF and FRET eff were significantly lower than in the experimental group. Swapping the donor and acceptor label still resulted in a detectable FRET signal between cav-1 and cav-2 although the signal was weaker (Figure 4) . No statistically significant difference in FRET signal was detected between the a10 nicotinic acetylcholine receptor and cav-1 and the negative control ( Figure 5 ). As a false-positive source for FRET we could occasionally detect changes in ROIs outside the bleached area that were not due to FRET but to movements of the specimen in z-direction that resulted from air movements of the air-conditioning system or from opening the door of the microscope room. Since these changes could be detected by our sentinel ROIs that were not bleached (cf. Figure 2) , these false-positive experiments could be readily identified and were excluded from further analysis.
Dilution Series of Cy3-Conjugated Secondary Antibody
To assess if crossreactivity of the secondary antibodies accounts for the FRET signal seen in negative controls, we simulated crossreactivity by detecting one primary antibody with two secondary anti- FRET in immunolabeled tissue sections P König et al bodies labeled with Cy3 and Cy5, respectively. Since both secondary antibodies used in this experiment bind to the same primary antibody (ie rabbit IgG) this situation is comparable to crossreactivity. The Cy3-labeled antibody was serially diluted to simulate lower amounts of bound crossreacting antibody. A high FRET signal up to 30% (median 21.98%) could be detected ( Figure 6 ) at the highest concentration of Cy3-labeled antibody used. Serial dilution of the Cy3-conjugated secondary reagent (donor) reduced FRET. At the highest dilution of 1:32 000 ( Figure 6 ) still FRET eff up to 12% (median 3.29%) was detected although Cy3 fluorescence was no longer microscopically visible and the DIF was small (median 0.82). This indicates that binding of minute amounts of Cy3-labeled antibody that results from minimal crossreactivity, can result in considerable FRET eff although the underlying DIF is minimal.
Comparison of Suitability of DIF and FRET eff to Detect FRET in Tissue Sections
Since high FRET eff can result from small increases in DIF that might result from crossreactivity of the donor-labeled secondary antibody if the initial donor fluorescence intensity is small, we assessed whether DIF is a better parameter to detect FRET in indirect immunofluorescence . For this purpose the ability of FRET eff and DIF to discriminate the control vs the experimental group was assessed by ROC curves (Figure 7) . The difference between both ROC curves was highly significant (Po0.001) indicating that DIF is superior to discriminate between FRET experiments vs control experiments ( Figure 7 ).
Incubation Sequence of Secondary Antibodies
Examination of the sequence of the application of the secondary antibodies revealed that incubation with the Cy5-conjugated secondary antibody (acceptor) before incubation of Cy3-conjugated secondary antibody (donor) resulted in higher FRET signal (median: FRET eff 6.64%, DIF 4.76) compared to incubation with Cy3-conjugated secondary antibody first (median: FRET eff 4.61%, DIF 2.19; Figure 8 ). FRET in immunolabeled tissue sections P König et al
Sequential Application vs Simultaneous Application of Secondary Antibodies and Use of F(ab 0 ) 2 Fragments vs Whole Secondary Antibodies
To assess if the size of the secondary antibody determines the intensity of the FRET signal, we tested if the use of a Cy5-labeled F(ab 0 ) 2 fragment instead of a Cy5-labeled whole IgG molecule resulted in higher FRET signal. In addition, we compared if the sequential application of both secondary antibodies is superior to mixing antibodies. To evaluate the influence of these factors we performed a variance analysis of the data. Mixing or sequential application alone had no significant influence on DIF (Figure 9 ). The choice of the secondary reagent had a significant influence on DIF (P ¼ 0.029) but this effect was also dependent on the mode of application (binding between F(ab 0 ) 2 and mixing, P ¼ 0.013). Explicitly, the F(ab 0 ) 2 fragment was superior when mixed but the whole molecule was better when applied sequentially ( Figure 9 ). These data indicate that all combinations tested in this experiment gave a robust FRET signal. In principle, neither the choice of the secondary reagent nor the mode of application can be regarded as superior.
Measurement of FRET in Human Glomus Tumors
To test the feasibility to apply the technique to human material we examined resection specimens . The endothelial cells of these enlarged vessels exhibited distinct cav-1-and cav-2 immunoreactivities. We were able to detect a robust FRET signal between cav-1 and cav-2 in these specimens ( Figure 10 ) (median DIF experimental group: 4.81, control: 1.25, Po0.001). This demonstrates that the technique can be used to analyze human material that is derived from surgical procedures and is stored for extended times at À801C.
Discussion
We were able to detect FRET in endothelial cells in tissue sections of rat and human specimens that were double labeled for cav-1 and cav-2 by indirect immunofluorescence. The interaction of both proteins was expected from biochemical experiments indicating that cav-1 and cav-2 form hetero-oligomers 15, 16 and that cav-2 needs cav-1 to be transported to the plasma membrane. 7, 8 Although the biochemical data predicted the close spatial association of both proteins in situ, this report shows for the first time this association in a specific cell type by light microscopy in tissue and provides the first description of cav-1 and cav-2 association in endothelial cells in human tissue.
Two additional experiments indicate that the detection of this interaction is specific. First, as expected, we did not detect a FRET signal between cav-2 and the a10 nicotinic acetylcholine receptor subunit. Second, we still detected an interaction between cav-1 and cav-2 when we switched the donor and the acceptor. Thus, detection of FRET does not depend on one particular set of secondary antibodies.
A major potential criticism of using indirect immunohistochemistry for FRET is the size of the antibody-antibody complexes used for detection. Could the size of the antibody-antibody complexes result in a FRET signal although the examined FRET in immunolabeled tissue sections P König et al maximal size of a primary antibody-secondary antibody complex is about 20 nm if they are linearly aligned. The maximal distance of two antibodyantibody complexes bound to cav-1 and cav-2 could be expected to be about 40 nm plus the distance between the binding sites of the antibodies and still give a FRET signal (Figure 11a ). If this scenario holds true, a FRET signal would still be expected to occur even if cav-1 and cav-2 were about 50 nm apart which is considerably more than the suggested 10 nm. However, several theoretical as well as practical considerations favor a scenario in which the two proteins are in fact clearly o50 nm apart (Figure 11b) . First, the fluorophores are most likely not exclusively located at the outermost part of the Fc part of the antibody. Second, a geometrical scenario that both secondary antibodies bind to the distal part of the Fc fragments and that these antibody-antibody complexes are lying flat on the caveolar membrane is highly unlikely. Third, if they did, they would have to be located in such a way that two Fc parts of the secondary antibodies point directly towards each other (cf. Figure 11a) . Most important, our data indicate that use of a F(ab 0 ) 2 fragment instead of a whole antibody molecule does not reduce the FRET signal as it would be expected if the antibodies bridged a larger distance. It is therefore highly unlikely that FRET signals based on indirect immunofluorescence occur with proteins that are not in close spatial association. In contrast, it is possible that although proteins interact, the method gives no FRET signal because the position of the antibody-antibody complexes towards each other is unfavorable.
Since cav-1 and cav-2 are present in multiple copies per caveola, sterical hindrance might also reduce the binding of secondary antibodies, resulting in lower FRET. Indeed, we observed higher FRET eff if the Cy5-conjugated secondary antibody was incubated prior to the Cy3-labeled antibody compared to the incubation of the Cy3-labeled antibody first. This indicates (1) that the secondary antibodies hinder each other's binding, and (2) that binding of larger amounts of acceptor (Cy5) can be favorable. A further result pointing in this direction is the higher FRET signal when the polyclonal cav-1 antibody was labeled with Cy5-conjugated antibody as compared to the labeling of the monoclonal cav-2 antibody with a Cy5-conjugated secondary antibody. Since polyclonal antibodies can bind to more than one epitope, the chance to bind to a protein is higher than with a monoclonal antibody. Thus, this could explain why we saw higher FRET signals when we labeled the polyclonal antibody with the acceptor (Cy5). Although we did see a clear difference between the application of Cy5-vs Cy3-conjugated secondary antibody first, we did not detect clear differences between Cy5 application first and simultaneous application of the secondary antibody. This indicates that simultaneous application of the secondary antibodies can result in sufficient amount of binding of acceptor-labeled antibodies to result in good FRET signal.
That acceptor bleaching is very well suited to detect FRET even if only small amounts of donor molecules are present is underpinned by our dilution experiments in which very small amounts of Cy3-conjugated antibody that are not seen microscopically still resulted in measurable FRET if Cy5 was present in large amounts. In our experiments, the only limiting factor to detect FRET is the stability of the setup and the bleaching of the donor during acceptor bleaching and image acquisition which can obscure small increases in donor fluorescence.
Surprisingly, we measured a FRET signal in control experiments when that primary antibody was omitted that was normally labeled with the Cy3-labeled secondary antibody and both secondary antibodies were applied. Although secondary anti- Figure 11 Possible spatial arrangements of antigen-antibody complexes. The spatial arrangement in (a) in which the antigens 1 and 2 are 50 mm apart and a FRET signal occurs is highly unlikely since the secondary antibodies have to bind to the tip of the Fc fragment of the primary antibody, the fluorophores have to be located at the tips of the secondary antibodies and both antibody-antigen complexes have to be aligned exactly. A much more likely configuration is that at least one of the antigenantibody complexes are arranged differently (asterisk) and no FRET occurs. If FRET is detected, a configuration as shown in (b) can be assumed in which both proteins 1 and 2 are in close apposition, the secondary antibodies do not bind to the tip of the bodies were crossadsorbed to the serum proteins of the other primary antibody's host species to reduce crossreactivity, the most likely explanation for this phenomenon is a minimal, yet measurable crossreactivity of the Cy3-conjugated secondary antibody. This is supported by the fact that in an experiment where both secondary antibodies were directed against the same primary antibody, FRET could be detected even if the concentration of the Cy3-conjugated secondary antibody was diluted up to the point that no Cy3 labeling was microscopically visible. Since FRET eff is the percentage of fluorescence increase, small changes in DIF result in large FRET eff if the initial Cy3 fluorescence intensity is low. This explains the rather large FRET eff in control sections in contrast to the small increase in DIF. Furthermore, the FRET signal measured under experimental conditions has to be interpreted as a mixture of two causes, first, the FRET eff resulting from labeling cav-1 and cav-2, and second, the crossreactivity of both secondary antibodies. Taking into consideration that crossreactivity of secondary antibodies results in binding of two antibodies to the same primary antibody, it should be expected that the resulting FRET eff is as high as or even higher than under experimental conditions where the secondary antibodies bind to different primary antibodies. Therefore, solely based on theoretical reasons FRET eff shall not be a reliable parameter to detect an association of two proteins by indirect immunohistochemistry and FRET. Indeed, statistical comparison of the ability of FRET eff and DIF to discriminate experimental and control conditions clearly shows that DIF is more sensitive and more specific to discriminate control from experimental conditions. We therefore propose DIF as the preferred parameter for measuring FRET in this setup provided both the control and the experimental conditions are measured under identical CLSM settings.
In addition to crossreactivity, we could identify another possible source that interferes with FRET measurements. We experienced that in some experiments DIF changed not only in the area that was bleached but also in areas outside the bleached ROI. We found that air movements that result from the air-conditioning system or from opening the door of the microscope room often also resulted in changes of DIF outside the bleached area. Therefore, it is mandatory to control for stability of the imaging system by measuring ROI outside the bleached area to validate if the measured changes indeed result from FRET or from movements of the specimen in z-direction.
If controlled properly, double-labeling immunofluorescence and FRET-CLSM hold strong promises to examine protein-protein association in tissue sections and can also be successfully used to examine such interactions in human material. Since the method is inexpensive, quick and requires only a standard CLSM that is accessible in most institutions, it opens up the possibility to gain insight in protein-protein interactions in tissue sections in normal as well as in human material derived from surgical procedures.
